Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study

Pascale Massin, Ali Erginay, Bénédicte Dupas, Aude Couturier, Ramin Tadayoni Ophthalmology Department, Lariboisière Hospital, Paris, France Purpose: To evaluate the efficacy and safety of sustained-delivery fluocinolone acetonide (FAc) intravitreal implant for diabet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Diabetic macular edema Intravitreal corticosteroid Corticosteroid intravitreal implant Fluocinolone acetonide. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/48c79ac13a9c422d994fff307ad1c065
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:48c79ac13a9c422d994fff307ad1c065
record_format	dspace
spelling	oai:doaj.org-article:48c79ac13a9c422d994fff307ad1c0652021-12-02T02:47:22ZEfficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study1177-5483https://doaj.org/article/48c79ac13a9c422d994fff307ad1c0652016-07-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-sustained-delivery-fluocinolone-acetonide-intra-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Pascale Massin, Ali Erginay, Bénédicte Dupas, Aude Couturier, Ramin Tadayoni Ophthalmology Department, Lariboisière Hospital, Paris, France Purpose: To evaluate the efficacy and safety of sustained-delivery fluocinolone acetonide (FAc) intravitreal implant for diabetic macular edema (DME). Patients and methods: Prospective study in patients with DME insufficiently responsive to laser and anti-vascular endothelial growth factor (anti-VEGF). Patients with history of rise of intraocular pressure after intravitreal corticosteroids were excluded. Results: The macular edema rapidly decreased both in group 1 (prior laser only; n=7 eyes) and group 2 (prior laser and ≥3 monthly anti-VEGF therapy; n=10 eyes) and central subfield thickness was reduced by -299 µm (P=0.008) and -251 µm (P=0.016) at 12 months, respectively. Mean area under the curve from baseline to last value for pseudophakic eyes was +4.2 letters in group 1 and +9.5 letters in group 2. Overall, the FAc implant was well tolerated. Conclusion: This prospective study confirms the efficacy of the FAc implant in DME patients insufficiently responsive to laser and anti-VEGF. Moreover, with a careful patient selection, our safety results would support an earlier use of FAc in the DME treatment pathway. Keywords: diabetic macular edema, intravitreal corticosteroid, corticosteroid intravitreal implant, fluocinolone acetonideMassin PErginay ADupas BCouturier ATadayoni RDove Medical PressarticleDiabetic macular edemaIntravitreal corticosteroidCorticosteroid intravitreal implantFluocinolone acetonide.OphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1257-1264 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diabetic macular edema Intravitreal corticosteroid Corticosteroid intravitreal implant Fluocinolone acetonide. Ophthalmology RE1-994
spellingShingle	Diabetic macular edema Intravitreal corticosteroid Corticosteroid intravitreal implant Fluocinolone acetonide. Ophthalmology RE1-994 Massin P Erginay A Dupas B Couturier A Tadayoni R Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
description	Pascale Massin, Ali Erginay, Bénédicte Dupas, Aude Couturier, Ramin Tadayoni Ophthalmology Department, Lariboisière Hospital, Paris, France Purpose: To evaluate the efficacy and safety of sustained-delivery fluocinolone acetonide (FAc) intravitreal implant for diabetic macular edema (DME). Patients and methods: Prospective study in patients with DME insufficiently responsive to laser and anti-vascular endothelial growth factor (anti-VEGF). Patients with history of rise of intraocular pressure after intravitreal corticosteroids were excluded. Results: The macular edema rapidly decreased both in group 1 (prior laser only; n=7 eyes) and group 2 (prior laser and ≥3 monthly anti-VEGF therapy; n=10 eyes) and central subfield thickness was reduced by -299 µm (P=0.008) and -251 µm (P=0.016) at 12 months, respectively. Mean area under the curve from baseline to last value for pseudophakic eyes was +4.2 letters in group 1 and +9.5 letters in group 2. Overall, the FAc implant was well tolerated. Conclusion: This prospective study confirms the efficacy of the FAc implant in DME patients insufficiently responsive to laser and anti-VEGF. Moreover, with a careful patient selection, our safety results would support an earlier use of FAc in the DME treatment pathway. Keywords: diabetic macular edema, intravitreal corticosteroid, corticosteroid intravitreal implant, fluocinolone acetonide
format	article
author	Massin P Erginay A Dupas B Couturier A Tadayoni R
author_facet	Massin P Erginay A Dupas B Couturier A Tadayoni R
author_sort	Massin P
title	Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
title_short	Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
title_full	Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
title_fullStr	Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
title_full_unstemmed	Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
title_sort	efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/48c79ac13a9c422d994fff307ad1c065
work_keys_str_mv	AT massinp efficacyandsafetyofsustaineddeliveryfluocinoloneacetonideintravitrealimplantinpatientswithchronicdiabeticmacularedemainsufficientlyresponsivetoavailabletherapiesareallifestudy AT erginaya efficacyandsafetyofsustaineddeliveryfluocinoloneacetonideintravitrealimplantinpatientswithchronicdiabeticmacularedemainsufficientlyresponsivetoavailabletherapiesareallifestudy AT dupasb efficacyandsafetyofsustaineddeliveryfluocinoloneacetonideintravitrealimplantinpatientswithchronicdiabeticmacularedemainsufficientlyresponsivetoavailabletherapiesareallifestudy AT couturiera efficacyandsafetyofsustaineddeliveryfluocinoloneacetonideintravitrealimplantinpatientswithchronicdiabeticmacularedemainsufficientlyresponsivetoavailabletherapiesareallifestudy AT tadayonir efficacyandsafetyofsustaineddeliveryfluocinoloneacetonideintravitrealimplantinpatientswithchronicdiabeticmacularedemainsufficientlyresponsivetoavailabletherapiesareallifestudy
_version_	1718402158352662528

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study

Ejemplares similares